The global extended release drugs market size was estimated to be US$ 46 billion in 2021 and is expected grow at a CAGR of 10.5% between 2023 to 2032.
The discovery of novel therapeutic compounds is an expensive and time-consuming process. Since the early 1960s, there has been a drop in the introduction of breakthrough chemical formulations due to rising R&D costs, alternative investment possibilities for pharmaceutical businesses, erosion of effective patent life, and declining commercial interests in funding pharmaceutical research.
Controlled release liposomal and inhalation delivery technologies can be used to solve a number of issues with conventional medication administration methods. These technologies, which are undoubtedly among the most cutting-edge and innovative medication delivery systems, are gaining popularity as choices for the treatment of pulmonary disorders.
Oral extended release tablets are referred to by a variety of terms, including modified release, prolonged release, controlled release, and sustained release. Oral extended release pharmaceuticals are products that customize either timing or rate of drug material release.
The market for oral extended release tablets will be influenced in the near future by the merits of oral extended release tablets over conventional dosage forms and an increase in research and development for novel drug discovery and therapy. Oral extended release tablets are in high demand due to a number of variables, including the increasing incidence of chronic conditions that require a drug's plasma concentration, the reduction of adverse effects, and improved patient compliance as a result of a reduced dosage.
The ongoing pharmacological failures are driving investors to become more cautious about their returns. In consequence, this is having a detrimental impact on the market for controlled release liposomal and inhalation delivery technologies. These technologies have a number of medically adverse disadvantages, including the fact that the majority of medications are quickly absorbed by the lungs, require periodic administration. The market's potential is being restricted by these therapeutically undesirable characteristics. Additionally, the healthcare changes implemented in a number of wealthy nations, namely the U.S., are hampering the market's expansion.
The market for oral extended release tablets may very well be curtailed by the need for expensive specialized equipment and inert ingredients for some controlled release formulations, which increases the expense of development. Food and gastric transit time also affect drug release, which results in differences in release rates between doses. Furthermore, chewing or breaking the oral extended release pills will result in their losing their slow release properties and become lethal.
Extended Release Drugs Market Share Analysis, by Geography (2021)
The major players covered in the extended release drug report are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, Ranbaxy and others.
Market Segmentation as below:
By Drug Release
By Distribution Channel
By Geography
Extended release drugs are in high demand due to a number of variables, including the increasing incidence of chronic conditions that require a drug's plasma concentration, the reduction of adverse effects, and improved patient compliance as a result of a reduced dosage.
The global extended release drugs market is estimated to exhibit a CAGR of 10.5% in terms of revenue over the forecast period 2023-2032.
Based on Drug Release, the extended release drugs market is segmented into Sustained release and Controlled Release.
Key extended release drugs market players are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, Ranbaxy and others.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved